-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCG-101 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCG-101 in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCG-101 in Hepatocellular Carcinoma Drug Details: SCG-101 is under development for the...
-
Company Insights
Innovation and Patenting activity of SCG Packaging PCL Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SCG Packaging PCL Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCG-101 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCG-101 in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCG-101 in Hepatocellular Carcinoma Drug Details: SCG-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PMD-026 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PMD-026 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PMD-026...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fadraciclib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fadraciclib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fadraciclib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ribociclib Succinate in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ribociclib Succinate in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ribociclib Succinate in Metastatic Colorectal Cancer Drug Details: Ribociclib...
-
Product Insights
Helicobacter pylori Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Helicobacter pylori Infections - Drugs In Development, 2023’, provides an overview of the Helicobacter pylori Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Pemphigus Foliaceus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Pemphigus Foliaceus Drug Details: Efgartigimod alfa-fcab (Vyvgart) is a human IgG1 antibody...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – UI-026 in Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UI-026 in Cough report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.UI-026 in CoughDrug Details:UI-026 is under development for the treatment of cough. The drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NO-13065 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NO-13065 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NO-13065 in Obesity Drug Details: NO-13065 is under development for the treatment...